Type II Kinase Inhibitors: An Opportunity in Cancer for Rational Design

Publisher： Bentham Science Publishers

E-ISSN： 1875-5992|13|5|731-747

ISSN： 1871-5206

Source： Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol.13, Iss.5, 2013-06, pp. : 731-747

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Kinase Inhibitors in Prostate Cancer

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 9, Iss. 10, 2009-12 ,pp. : 1089-1104

Bentham Science Publishers

Access to resources Recommend Favorite

Preclinical Development of Novel Rac1-GEF Signaling Inhibitors using a Rational Design Approach in Highly Aggressive Breast Cancer Cell Lines

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 14, Iss. 6, 2014-07 ,pp. : 840-851

Bentham Science Publishers

Access to resources Recommend Favorite

Type II cGMPdependent protein kinase inhibits epidermal growth factorinduced phosphatidylinositol3kinase/Akt signal transduction in gastric cancer cells

By              

Oncology Letters, Vol. 6, Iss. 6, 2013-01 ,pp. : 1723-1728

Spandidos Publications

Access to resources Recommend Favorite

Type II cGMP-dependent protein kinase inhibits ligandinduced activation of EGFR in gastric cancer cells

By              

Molecular Medicine Reports, Vol. 9, Iss. 4, 2014-01 ,pp. : 1405-1409

Spandidos Publications

Access to resources Recommend Favorite

Type II cGMPdependent protein kinase inhibits RhoA activation in gastric cancer cells

By          

Molecular Medicine Reports, Vol. 9, Iss. 4, 2014-01 ,pp. : 1444-1452

Spandidos Publications

Access to resources Recommend Favorite